Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...